Mycoplasma

Mycoplasma refers to a group of small bacteria lacking cell walls, capable of contaminating mammalian cell cultures and posing significant risks to biopharmaceutical research and manufacturing. Because mycoplasma infections often do not cause obvious turbidity or visible contamination, they can persist undetected while altering cell metabolism, growth rates, gene expression, and protein production, compromising experimental validity and product quality.

The biopharmaceutical industry treats mycoplasma control as a fundamental requirement for GMP compliance and patient safety. Manufacturing processes involving mammalian cells require routine mycoplasma testing at defined stages, including cell bank qualification, in-process monitoring, and final product release, using validated methods such as PCR, culture-based assays, and indicator cell tests. Contamination events can result in batch failures, facility shutdowns, and significant financial losses, making prevention strategies essential. Risk mitigation includes strict aseptic technique, quarantining incoming cell lines, supplier qualification for raw materials, and robust environmental monitoring. Regulatory expectations require documented mycoplasma control strategies and immediate corrective actions when contamination is detected. As advanced cell therapies and viral vector manufacturing expand, mycoplasma prevention and detection remain central to ensuring consistent product quality and protecting patients from microbial risk.